Clinical Trials
9 trialsNCT06237881 2026-02-18
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03991741 2025-07-03
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
Phase 1 Terminated
NCT04166006 2024-09-19
RaC-Ad
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT04729543 2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2 Recruiting
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT05122221 2022-06-28
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Unknown
NCT00006033 2013-05-30
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00937300 2011-11-23
T-cell Based Immunotherapy for Head and Neck Cancer
Herlev Hospital
Phase 1 Withdrawn